India’s pharma sector eyes modest FY growth as US market clouds loom

India’s pharmaceutical sector anticipates moderate growth in FY2026, with revenues projected to rise by 7-9%. Domestic market expansion and European growth will fuel this, while the US market faces headwinds due to price erosion and declining sales of key drugs. Operating profit margins are expected to remain strong, supported by favorable raw material prices and specialty products.